PCSK9 Inhibitors in Cardiovascular Disease
This webinar presentation will outline the role of PCSK9 inhibitors in the management of cardiovascular patients and identify which patient groups are best suited to the use of these agents.
- Discuss the role of PCSK9 inhibitors in the management of cardiovascular disease
- Outline which patient groups are best suited to the use of these agents
- Develop monitoring strategies to assess the efficacy and toxicity of these agents.
7. 1 Contribute to therapeutic decision making
7.2 Provide ongoing medication management
7.3 Influence patterns of medicine use
(National Competency Standards Framework for Pharmacists in Australia, 2010)
Free to Members: Register here
Presenter: Jeanie Misko, Senior Medicines Information Senior Pharmacist, Fiona Stanley Hospital, B.Pharm (Curtin) PGDipPharm (Curtin), M.Pharm (Clin Pharm) (Curtin), PGDipOncology (Newcastle University UK) and Recipient of the Novartis SHPA Pharmacoeconomics Grant 2016 and MSHP